Erasca jumps as ERAS-0015 shows early Phase 1 tumor responses at low dose
Erasca shares rose after the company highlighted early Phase 1 responses for its pan-RAS molecular glue ERAS-0015, including confirmed partial responses in multiple tumor types at an 8 mg once-daily dose. The update also pointed to favorable safety so far, with no dose-limiting toxicities reported during dose escalation as of a January 7, 2026 data cutoff. (investors.erasca.com)
1) What’s driving ERAS today
Erasca (ERAS) is moving higher as investors react to its latest clinical update on ERAS-0015, an experimental pan-RAS molecular glue being studied in the AURORAS-1 Phase 1 dose-escalation trial. The company reported early anti-tumor activity that included confirmed partial responses across multiple tumor types and RAS mutations, which is fueling renewed optimism that the program could differentiate in a crowded RAS-targeting landscape. (investors.erasca.com)
2) Key data points investors are focusing on
In the update, Erasca disclosed two confirmed partial responses and one unconfirmed partial response at a low 8 mg once-daily dose, plus additional ongoing unconfirmed responses at higher doses. Management also emphasized tolerability to date, citing no dose-limiting toxicities and predominantly low-grade adverse events across evaluated dose levels, alongside linear pharmacokinetics with no exposure plateau. (investors.erasca.com)
3) What comes next: 2026 milestones
Erasca has guided to initial Phase 1 monotherapy data for ERAS-0015 in the first half of 2026, with ERAS-4001 initial Phase 1 monotherapy data planned for the second half of 2026. With both programs aimed at shutting down RAS/MAPK signaling, upcoming readouts and expansion/combination plans are likely to remain the primary catalysts for the stock. (investors.erasca.com)